187 related articles for article (PubMed ID: 20035679)
21. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
Ng CM; Fielder PJ; Jin J; Deng R
AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
[TBL] [Abstract][Full Text] [Related]
22. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system.
Guilleminault L; Azzopardi N; Arnoult C; Sobilo J; Hervé V; Montharu J; Guillon A; Andres C; Herault O; Le Pape A; Diot P; Lemarié E; Paintaud G; Gouilleux-Gruart V; Heuzé-Vourc'h N
J Control Release; 2014 Dec; 196():344-54. PubMed ID: 25451545
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins.
Ternant D; Paintaud G
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S37-47. PubMed ID: 16187939
[TBL] [Abstract][Full Text] [Related]
24. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
25. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
26. Impact of altered endogenous IgG on unspecific mAb clearance.
Fuhrmann S; Kloft C; Huisinga W
J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
[TBL] [Abstract][Full Text] [Related]
27. Target-independent variable region mediated effects on antibody clearance can be FcRn independent.
Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD
MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650
[TBL] [Abstract][Full Text] [Related]
28. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
[TBL] [Abstract][Full Text] [Related]
29. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.
Ramdani Y; Lamamy J; Watier H; Gouilleux-Gruart V
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077002
[TBL] [Abstract][Full Text] [Related]
31. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
[TBL] [Abstract][Full Text] [Related]
32. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
Maas BM; Cao Y
MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
[TBL] [Abstract][Full Text] [Related]
33. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
Liu L
Protein Cell; 2018 Jan; 9(1):15-32. PubMed ID: 28421387
[TBL] [Abstract][Full Text] [Related]
35. [Neonatal Fc receptor, key control of immunoglobulins biodistribution].
Magdelaine-Beuzelin C; Ohresser M; Watier H
Med Sci (Paris); 2009 Dec; 25(12):1053-6. PubMed ID: 20035678
[TBL] [Abstract][Full Text] [Related]
36. Incorporation of FcRn-mediated disposition model to describe the population pharmacokinetics of therapeutic monoclonal IgG antibody in clinical patients.
Ng CM
Biopharm Drug Dispos; 2016 Mar; 37(2):107-19. PubMed ID: 26581439
[TBL] [Abstract][Full Text] [Related]
37. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
38. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.
Li L; Gardner I; Dostalek M; Jamei M
AAPS J; 2014 Sep; 16(5):1097-109. PubMed ID: 25004823
[TBL] [Abstract][Full Text] [Related]
39. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
Matera MG; Calzetta L; Rogliani P; Cazzola M
Respir Med; 2019 Jul; 153():3-13. PubMed ID: 31136930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
